<DOC>
	<DOC>NCT00326248</DOC>
	<brief_summary>This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.</brief_summary>
	<brief_title>Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Inclusion criteria: History of PONV and/or motion sickness. Have not smoked for the last 6 months. Having certain types of abdominal, breast or shoulder surgeries. Exclusion criteria: Pregnant or breastfeeding. Taking certain medications. Have certain preexisting medical conditions.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>postoperative nausea and vomiting PONV antiemetics NK-1 5HT3 casopitant mesylate ZOFRAN ondansetron hydrochloride</keyword>
</DOC>